natgillin/translations-raw huggingface dataset:
A process for preparing a compound as claimed in claim 1, characterized by reacting an intermediate of formula (II) with an appropriate acid yielding a hydroxamic acid of formula (I), 
Proces za pripremu spoja prema zahtjevu 1, naznačen time, da intermedijer sa formulom (II) reagira sa odgovarajućom kiselinom, a to dovodi do nastanka hidroksamske kiseline sa formulom (I).
It is preferred that the neurodegenerative disease is selected from the group consisting of Alzheimer's disease, Parkinson's disease, and stroke. 
Farmaceutski pripravak za uporabu prema zahtjevu 5, naznačen time da neurodegenerativna bolest je odabrana iz skupine koju čine Alzheimerova bolest, Parkinsonova bolest,, i kap.
Layer 3 consists of 33.3% w/w PLA, 33.3% w/w PBSA and 33.3% w/w PBAT, wherein layer 2 is sandwiched between layers 1 and 3. 
PLA, 33,3% tež./tež. PBSA i 33,3% tež./tež. PBAT, pri čemu je sloj 2 postavljen poput sendviča između slojeva 1 13.
A vector comprising the nucleic acid molecule according to embodiment 46. 
Vektor koji sadrži molekulu nukleinske kiseline sukladno patentnom zahtjevu 8.
A 1.0 mg/mL solution can be made by dilution of 25.0 mL of the 4.0 mg/mL solution to 100.0 mL with placebo. 
1.0 mg/mL otopina može se pripraviti razrjeđivanjem 25.0 mL 4.0 mg/mL otopine u 100.0 mL sa placebom. HR P20070534 T3
Process for the preparation of complexes of iron (III) hydroxide and activated glucose syrup, wherein the molecular weight of the complex is in the range of from 100 kDa to 150 kDa, as measured by high performance liquid chromatography-gel permeation chromatography (HPLC-GPC), said process comprising the steps: 
Proces za pripremu kompleksnih spojeva željezo (III) hidroksida 1 aktiviranog glukoznog sirupa, pri čemu je molekularna težina kompleksa u rasponu od 100 kDa do 150 kDa, kako je izmjereno tekućinskom kromatografijom visokog učinka - gel permeacijskom kromatografijom (HPLC-GPC), naveden proces sadrži slijedeće korake:
An orally administrable chewable pharmaceutical composition in unit dosage form comprising an oil-in-water emulsion in which the aqueous phase is gelled and in which the oil phase comprises a physiologically tolerable unsaturated fatty acid ester, wherein the aqueous phase comprises a physiologically active agent, or the oil phase comprises a physiologically tolerable lipid soluble material which is physiologically active. 
Oralno primjenjiv pripravak za žvakanje u obliku jedinične doze koji sadrži ulje-u-vodi emulziju gdje je vodena faza gelirana i gdje uljna faza obuhvaća riblje ulje, pri čemu je težina te jedinične doze 0.25-3g.
In certain embodiments, each cytosine of a modified oligonucleotide comprises a 5-methylcytosine. 
PATENTNI ZAHTJEVI Spoj koji sadrži modificirani oligonukleotid koji se sastoji od nukleobazne sekvence i modifikacija:
The process of claim 7, wherein the concentration of H2SO4 is from 25 g/L to 35 g/L, and wherein the concentration of HF is from 0 g/L to 100 g/L. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što se koncentracija H2SO4 kreće od 25 g/l do 35 g/l, a koncentracija HF se kreće od 0 g/l do 100 g/l.
is O, S, NH or N(lower alkyl); n is 0, 1 or 2; or a pharmaceutically active acid addition salt thereof. 
X je O, S, NH ili N(C,-C; alkil); nje 0, 1ili 2; i farmaceutski aktivne soli uz dodatak kiseline.
The process according to Claim 26, characterized in that the temperature in the first insulator is in the range of approximately 20 to approximately 50°C and the temperature in the second insulator is in the range of approximately -5 to approximately +25°C. 
Postupak prema Zahtjevu 26, naznačen time da je temperatura u prvom izolatoru u rasponu od približno 20 do približno 50" i temperatura u drugom izolatoru je u rasponu od približno -5 do približno +25"C.
A compound according to claim 1, wherein the compound of formula (Ia″) is a compound of formula (I-T23) 
6. - Spojevi prema zahtjevu 1, naznačeni time da spojevi s formulom (Ia") su spojevi s formulom (I-T23)
A dispenser according to any preceding clause, wherein the limiting mechanism comprises a guide, the guide comprising an arm spaced apart from the limiting member engaging portion in a fixed relation, the guide being configured to contact the first ring member such that the limiting member engaging portion maintains contact with the first ring member. A dispenser according to clause 7, wherein the guide contacts the first ring member on an outer circumferential surface. 
Dispenzer u skladu sa bilo kojim od patentnih zahtjeva 18 do 21, gdje mehanizam za ograničavanje sadrži vođicu, pri čemu vođica sadrži ruku koja je odmaknuta od dijela za angažiranje elementa za ograničavanje u fiksiranom odnosu, pri čemu je vođica konfigurirana da kontaktira prvi prstenasti element sa prstenom tako da dio za angažiranje elementa za ograničavanje održava kontakt sa prvim prstenastim elementom.
The composition of clause 36 comprising at least about 20 moles of the boronic ester compound of formula (I). 
Kompozicija prema patentnom zahtjevu 22, koja sadrži najmanje 20 mola spoja estera organoborne kiseline formule (7).
The reaction is conveniently carried out in the presence of a suitable inert solvent or diluent, for example an alcohol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran or 1,4-dioxane, an aromatic solvent such as toluene, or a dipolar aprotic solvent such as N, N -dimethylformamide, N,N -dimethylacetamide, N -methylpyrrolidin-2-one acetonitrile or dimethylsulfoxide. 
Reakcija se prikladno provodi u prisutnosti prikladnog inertnog otapala ili razrjeđivača, na primjer, alkohola ili estera poput metanola, etanola, izopropanola ili etil-acetata, halogeniranog otapala poput metilen-klorida, kloroforma ili ugljik- tetraklorida, etera poput tetrahidrofurana ili 1,4-diokasana, aromatskog otapala poput toluena, ili dipolarnog aprotičkog otapala poput N,N-dimetilformamida, N,N-dimetilacetamida, N-metil-pirolidin-2-onacetonitrila ili dimetilsulfoksida.
The aqueous pharmaceutical composition for use according to claim 10, 11, 12 or 13, wherein said pharmaceutical composition further comprises 0.1 µg to 10 µg lixisenatide per U insulin glargine. 
Vodena formulacija za uporabu prema zahtjevu 22 naznačena time da navedeni farmaceutski pripravak nadalje sadrži 0.1 µg do 10 µg liksisenatida po jedinici inzulin glargina.
Cortexolone-17a-propionate in crystalline form I according to any one of claims 17 to 18 for use in treating pathologies affecting the urogenital system, the endocrine system, the skin and/or the cutaneous appendages. 
Korteksolon-17a-propionat u hidratnom kristalnom obliku IV u skladu s bilo kojim od patentnih zahtjeva 21 do 22, naznačen time što je namijenjen upotrebi u liječenju patoloških pojava koje pogađaju urogenitalni sustav, endokrini sustav, kožu i/ili kožnih adneksa.
injection, preferably intravenous injection, to said subject, said administration causing infection of motor neurons or glial cells and expression of the gene in motor neurons or glial cells, wherein said AAV vector is: 
injiciranjem, poželjno intravenskim injiciranjem, navedenom subjektu, navedena primjena uzrokuje infekciju motoričkih neurona ili glija stanica 1 ekspresiju gena u motoričkim neuronima ili glija stanicama, pri čemu je navedeni AAV vektor:
The silicate can contain potassium and lithium in a ratio of K2O:Li2O ranging between 20:1 to 3:1, more preferably in the ratio of K2O:Li2O ranging between 15:1 to 4:1, and most preferably in the ratio of K2O:Li2O ranging between 11:1 to 7:1, with all ratios expressed herein by weight. 
Gusta smjesa 1z patentnog zahtjeva 1, pri čemu kalijev silikat obogaćen litijem sadrži kalij 1 litij u masenom omjeru 3:1 do 20:1 kao K20:L10, 1 nadalje gdje je maseni omjer silikata prema kaliju od 2:1 do 3:1 kao SiO»:K20.
The vesicles for use according to claim 14, wherein the complex wound is a diabetic foot ulcer, a venous ulcer, a decubitus ulcer or a burn. 
15. Čestice za uporabu prema patentnom zahtjevu 14, pri čemu je složena rana ulkus dijabetičkog stopala, venski ulkus, dekubitalni ulkus ili opeklina.
In some embodiments, Ring A is a 5-membered heterocyclic ring. 
U nekim oblicima, Prsten A je 5-člani heterociklički prsten.
In certain embodiments, the pre-fusion RSV F polypeptides comprise at least one further mutation, selected from the group consisting of: 
Prefuzijski RSV F polipeptid prema zahtjevu 5, naznačen time što je najmanje jedna daljnja mutacija odabrana iz skupine koja sadrži:
The three filtration stations 15a, 15b, 15c are similar in that they present the same components. 
Tri stanice za filtriranje 15a, 15b, 15c su slične po tome što one imaju iste komponente.
The pharmaceutical composition according to claim 12, further comprising a pharmaceutically acceptable carrier. A method of treating heart failure, congestive heart failure, cardiomyopathy, myocardial infarction, left ventricular dysfunction, cardiac hypertrophy, valvular heart diseases, hypertension, atherosclerosis, peripheral arterial occlusive disease, restenosis, vascular permeability disorders, treatment of edema, thrombosis, rheumatoid arthritis, osteoarthritis, renal failure, cystic fibrosis, chronic bronchitis, chronic obstructive pulmonary disease, asthma, immunological diseases, diabetic complications, fibrotic diseases, pain, ischemia or reperfusion damage or neurodegenerative diseases, or for cardioprotection or renoprotection or as a diuretic (stand-alone treatment or in combination with established diuretics) in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition of claim 12 . 
Upotreba spoja formule I u skladu s bilo kojim od jednog ili više patentnih zahtjeva 1 do 9, ili njegove fiziološki prihvatljive soli, ili fiziološki prihvatljivog solvata bilo kojeg od njih, naznačena time što je spoj namijenjen proizvodnji medikamenta za liječenje srčane insuficijencije, kongestivne srčane insuficijencije, kardiomiopatije, infarkta miokardia, disfunkcije lijeve klijetke, srčane hipertrofije, bolesti srčanih zalistaka, hipertenzije, ateroskleroze, okluzivne bolesti perifernih arterija, restenoze, poremećaja propusnosti srčanih zalistaka, liječenje edema, tromboze, reumatoidnog artritisa, osteoartritisa, bubrežne insuficijencije, cistične fibroze, kroničnog bronhitisa, kronične opstruktivne plućne bolesti, astme, imunoloških bolesti, dijabetičnih komplikacija, fibrotičnih bolesti, boli, ishemije ili reperfuzijskog oštećenja ili neurodegenerativnih bolesti, ili za kardioprotekciju ili renoprotekciju ili kao diuretik (samostalno liječenje ili u kombinaciji s postojećim diureticima).
In one embodiment, R2 is selected from the group consisting hydrogen, 
R2 je odabran iz skupine koja sadrži (1) vodik,
wherein X is OH or a leaving group, to form a compound of formula (XXIII): and 
HR P20110846 T1 gdje X je OH ili odlazeća grupa, tako da se formira spoj formule (XXIII):
The compound according to claim 6 or a salt thereof, or a hydrate or a solvate thereof, wherein R29 is a C1-6 alkyl group substituted with a C1-6 alkylsulfonyl group. 
Spoj u skladu s patentnim zahtjevom 6 ili sol istog ili hidrat ili solvat istog, naznačen time, da R29 jeste C1-6 alkilna skupina supstituirana s C1-6 alkilsulfonilnom skupinom.
further reducing the compound XII, if Y is a hydroxyl group, to obtain a compound, in which Y is hydrogen, in a B type-stereoselective manner; and if desired, further deprotecting the compound obtained in (1) or (2), in accordance with the following scheme: 
(2) daljnju redukciju spoja XII, ako Y je hidroksil skupina, da se dobije spoj, u kojem Y je vodik, na stereoselektivni način f-tipa; te ako se želi, daljnje deprotekcije spoja dobivenog u (1) ili (2), u skladu sa slijedećom shemom:
The ship according to claim 1 characterized by the fact that the rod (41) of the hydraulic jack (4) is connected to the angular zone of the dihedron of the deflector member (1). 
Brod prema zahtjevu 1, naznačen time da je klipnjača (41) hidrauličke dizalice (4) spojena na kutnu zonu dihedrona elementa za skretanje (1).
The entire process takes place in a heterogeneous system, which makes intermixing of reactants difficult. 
Cijeli postupak odvija se u heterogenom sistemu, što otežava miješanje.
conjugating a capsular polysaccharide to a carrier protein, 
kapsularni polisaharid koji je dobiven u koraku a) je konjugiran na protein nosač.
Elution with hexanes-ethyl acetate (3:1) gave title compound as yellowish foam (5.4 g). 
Elucija s heksanima - etil-acetatom (3:1) daje spoj iz naslova kao žučkastu pjenu (5,4 g).
A composition according to claim 1, wherein component (B) is selected from the group consisting of 
Pripravak prema zahtjevu 1, naznačen time da je komponenta (B) odabrana iz skupine koja se sastoji od (Bl)
The immunogenic composition of claims 1-5 wherein the carrier protein is selected from the group consisting of: TT, DT, CRM197, fragment C of TT and protein D. 
Postupak u skladu s patentnim zahtjevima 1-9, naznačen time što se proteinski nosač bira iz skupine koju čine: TT, DT, CRM197, fragment C od TT, protein D iz bakterije H. influenzae, pneumokokni PhtD, te pneumokokni pneumolizin.
The platform according to claim 23, wherein said oral cephalosporin is selected from the group consisting of Cefalexin, cefuroxime, cefadroxil and cefaclor. 
Platforma prema zahtjevu 12, gdje je fluorokinolon Ciprofloksacin i/ili gdje je oralni cefalosporin izabran iz grupe koja obuhvaća Cefaleksin, cefuroksim, cefadroksil i cefaklor,
The boom mountable robotic arm of claim 6 wherein said electrically insulated support post includes an insulated upright portion and a riser portion, said riser portion having a first end pivotably connected to said upper beam assembly and a second end supporting said insulated upright portion, and wherein said actuator angularly extends from said second end of said riser portion to said upper beam assembly. 
Robotska ruka koja se može montirati na krak dizalice prema zahtjevu 1, naznačena time, da navedeni električno izolirani podupirač uključuje izolirani uspravni dio 1 podizni dio, gdje navedeni podizni dio ima prvi kraj stožerno spojen na navedeni gornji gredni sklop te drugi kraj koji pridržava navedeni izolirani uspravni dio, te se pritom aktivator proteže pod kutom iz navedenog drugog kraja od navedenog podiznog dijela prema navedenom gornjem grednom sklopu.
is selected from the group consisting of H, alkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, arylalkyl, heteroaryl and heteroarylalkyl; 
R$ je izabran iz skupine koja se sastoji od H, alkil, cikloalkil, cikloalkilalkil, heterociklil, heterociklilalkil, aril, arilalkil, heteroaril i heteroarilalkila;
a phenyl group, a naphthyl group or an isoquinolinyl group, each of which may be substituted with 1 to 3 substituents selected from the group B [wherein the group B consists of a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group, an amino group which may be substituted with one or two C1-C6 alkyl groups, a morpholino group, a piperazino group which may be substituted with a C1-C6 alkyl group(s), a C1-C6 alkanoylamino group, and a C1-C6 alkylsulfonylamino group], 
(iii) fenilnu skupinu, naftil skupinu ili izokinolinil skupinu, od kojih svaka može biti supstituirana sa 1 do 3 supstituenta odabrana iz skupine B [pri čemu skupina B sadrži atom halogena, C;-Cg alkilnu skupinu, C;- CÂ« alkoksi skupinu, amino skupinu koja može biti supstituirana sa jednom ili dvije Cy-Cg alkilne skupine,
The patent application is illustrated by the drawings wherein: 
Datum objave europske prijave patenta:
In one embodiment, the luteinising hormone (LH) is present at a concentration of at or about 0.1 to 1 ug/mg of the total formulation. 
Smrzavanjem osušena formulacija prema zahtjevu 9, naznačena time da je luteimizirajući hormon (LH) prisutan u koncentraciji od ili oko 0.1 do 1 ug/mg ukupne formulacije.
For example, R1 may be methyl. 
Na primjer, R' može biti metil.
The composition or vaccine of any one of claims 1-3 for use in a method for inducing a protective response in an animal against NDV and optionally one or more further avian pathogens, said method comprising at least one administration of the composition or vaccine. 
Vektor prema zahtjevu 10, naznačen time, da se upotrebljava u postupku induciranja imunosnog ili zaštitnog odgovora kod životinje protiv jednog ili više ptičjih patogena, pri čemu navedeni postupak obuhvaća najmanje jednu primjenu spomenutog sastava ili cjepiva.
The solid dosage form of claim 6, wherein the proportion of hydroxypropyl methyl cellulose is about 7% (w/w) of the total formulation. 
Čvrsti oblik doziranja u skladu s patentnim zahtjevom 9, naznačen time što je udio hidrofilnog veziva 7% (tež./tež.) od ukupne formulacije.
Multi-purpose truck for re-establishment of safe and practicable road conditions, after car accidents, through cleaning of the road platform, according to claim 1, further comprising: 
Višenamjenski kamion (100) za ponovno uspostavljanje sigurnih i prohodnih uvjeta na cesti nakon automobilskih nezgoda, čišćenjem cestovne plohe, prema jednom ili više prethodnih patentnih zahtjeva od 5 do 8, naznačen time, da
The conjugates made by the above methods can be purified by standard chromatography techniques such as size-exclusion, adsorption chromatography including, but not limited to, ion exchange, hydrophobic interaction chromatography, affinity chromatography, chromatography on ceramic hydroxyapatite or on Porapak, or by HPLC. 
Postupak u skladu s patentnim zahtjevima 8 do 10, naznačen time što se konjugat pročišćuje gel-permeacijskom kromatografijom, adsorpcijskom kromatografijom, ionoizmjenjivačkom kromatografijom, kromatografijom uz hidrofobno međudjelovanje, afinitetnom kromatografijom, HPLC-om, kromatografijom na hidroksiapatitu, dijalizom ili dijafiltracijom.
Dextran sulfate, or a pharmaceutically acceptable derivative thereof, having an average molecular weight equal to or below 10 000 Da for use in increasing blood flow in a subject suffering from ischemia. 
Dekstran sulfat ili njegov farmaceutski prihvatljiv derivat, koji ima prosječnu molekularnu masu jednaku ili ispod 10000 Da, naznačen time što se koristi za povećanje protoka krvi kod subjekta koji pati od ishemije.
at least 12 unrearranged human Vλ gene segments; or 
(a) najmanje 12 nepreuređenih humanih segmenata gena V2; ili
The anti-CD52 antibody for use according to claim 31, wherein the multiple sclerosis is relapsing remitting multiple sclerosis. 
Anti-CD52 protutijelo za uporabu prema zahtjevu 31, naznačeno time da multipla skleroza je relapsno-remitirajuća multipla skleroza.
The solid is washed with a mixture of 1.6 kg of anhydrous ethyl acetate and 0.14 kg of i -propanol cooled at 0-5°C. The solid is dried in a vacuum oven at 50°C for a minimum period of 12 hours. 
Krutina se ispere s mješavinom od 1,6 kg bezvodnog etil acetata i 0,14 kg i-propanola ohlađenog na 0-5 *C. Krutina sc osuši u vakuumskoj pećnici pri 50*C tijekom minimalno 12 sati.
A method as claimed in claim 14 wherein after step (iv) there is provided the further step of subjecting said thermally insulating stretchable down feather sheet (10) to a cooling airflow. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što se nakon koraka (iv) provodi dodatni korak izlaganja navedenog toplinski izolirajućeg rastezljivog sloja paperja (10) struji zraka za hlađenje.
providing of electrical spot welding equipment and then performing a spot welding action for each locally welded joint, wherein the first and the second metal plate are brought into electrical connection with a first and a second welding current connection of the spot welding equipment, and the first and second metal plate are pressed locally towards each other in such a way, that mutual electrical contact is made, so that a local welding current occurs between the metal sheets, and that both metal plates are welded together at those locations. 
osiguravanju opreme za električno točkasto zavarivanje, a zatim 1 provođenja točkastog zavarivanja za svaki lokalno zavareni spoj, gdje se prvu i drugu metalnu ploču dovede u električnu vezu s prvim 1 drugim kontaktom za ostvarivanje struje zavarivanja opreme za točkasto zavarivanje, gdje se prvu 1 drugu metalnu ploču tako pritisne lokalno jednu prema drugoj da se načini uzajamni električni kontakt, tako da se pojavi lokalna struja zavarivanja između slojeva metala, te se obje metalne ploče zavari zajedno na tim mjestima.
The invention also concerns the antibody of the invention as a medicament. 
Antitijelo ili njegov dvovalentni funkcionalni fragment iz patentnih zahtjeva 1 do 6, za upotrebu kao lijek.
The process according to claim 5, wherein at least one bioavailable iron salt is ferric saccharate. 
Postupak u skladu s patentnim zahtjevom 10, naznačena time što je najmanje jedna biodostupna željezna sol feri saharat.
The crude residue is dissolved in 1:1 THF/water and acidified to pH 3-4 using 6M HCl. 
Sirov ostatak se otopi u 1:1 THE/vodi i zakiseli se na pH 3-4 upotrebom 6M HCI1.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, le kao komponentu (B) fluopiram.
Composition according to any one of claims 1 to 9 wherein the water content of the donepezil hydrochloride hydrate and the various excipients used in the composition is adjusted in such a way that a migration of water from the excipients to the donepezil hydrochloride or vice versa is prevented. 
Pripravak prema bilo kojem od patentnih zahtjeva 1 do 9, takav da je sadržaj vode donepezil hidroklorid hidrata i različitih ekscipijensa korištenih u pripravku prilagođen na takav način da je prelazak vode sa ekscipijensa na donepezil hidroklorid ili obrnuto spriječen.
The method of claim 1, where the crystalline hydrochloride salt is characterized by a differential scanning calorimetry trace substantially in accordance with that shown in FIG. 
Spoj sukladno patentnom zahtjevu 1, naznačen time, da mu trag diferencijalne pretražne kalorimetrije u biti u skladu s onim koji je prikazan na SI.
The process according to claim 1, wherein the natural calcium carbonate is treated with the acid and the carbon dioxide in the presence of at least one silicate, silica, aluminium hydroxide, earth alkali metal aluminate, magnesium oxide, or mixtures thereof. The process according to claim 11, wherein the at least one silicate is an aluminium silicate, a calcium silicate, or an earth alkali metal silicate. 
Postupak prema jednom od prethodnih zahtjeva, pri čemu prirodni kalcij karbonat reagira sa kiselinom i/ili ugljičnim dioksidom u prisutnosti barem jednog spoja izabranog iz skupine koja se sastoji od silikata, poželjno izabranog od aluminij silikata, kalcij silikata, ili zemno alkalnog metalnog silikata; silike, aluminij hidroksida, zemno alkalnog metalnog aluminata, magnezij oksida, ili njihovih smjesa.
Use of the isolated monoclonal antibody or antigen-binding fragment according to any of claims 1-9, for the manufacture of a medicament for the treatment of atopic dermatitis, dermatitis, prurigo nodularis, eczema, pruritus, vitiligo, alopecia aerata, acne rosacea, acne vulgaris, bullous pemphigoid or contact dermatitis. 
Primjena izoliranog monoklonskog antitijela ili antigen-vezujućeg fragmenta u skladu sa bilo kojim od patentnih zahtjeva 1-5, za proizvodnju lijeka za liječenje atopijskog dermatitisa, dermatitisa, prurigo nodularis, ekcema, pruritusa, vitiliga, alopecia aerata, acne rosacea, acne vulgaris, buloznog pemfigoida ili kontaktnog dermatitisa.
Additionally, the formulation can also comprise an analogue of exendin-4, such, for example, lixisentatide, exenatide and liraglutide. 
Vodena formulacija u skladu s patentnim zahtjevom 1, naznačena time što sadrži analog eksendina-4, kojeg se bira iz skupine koju čine liksisenatid, eksenatid i liraglutid.